NAQI SA
6.3 FTENAQI reported total assets of €1.25m at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026), with 6.3 full-time equivalents.
The score of NAQI shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -52 % Total assets +2 % Headcount (avg FTE) +37 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
NAQI's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −12,551 € | ||||
| Equity | 106,161 € | ||||
| Cash | 25,269 € | ||||
| EBITDA | 126,752 € | ||||
| Total assets | €1.25m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2024filed on 28 Jul 2025
- Year ended 31 Dec 2023filed on 27 Aug 2024
- Year ended 31 Dec 2022filed on 29 Aug 2023
- Year ended 31 Dec 2021filed on 26 Aug 2022
NAQI's financial analysis
- Solvency8.5%sector median: 47.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of NAQI
NAQI's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0428.898.564
- VAT number
- BE0428898564
- Peppol
- Registered · 0208:0428898564 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 15 May 1986
- Registered office
- 3545 Halen
- Size
- Micro · 6.3 FTE
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Manufacture of medicaments (NACE 21201)
NAQI (SA) has been based in Halen since 1986, active in: manufacture of medicaments. For 2025, it reports a net loss of 12,551 € and equity of 106,161 €; its revenue is not published. With 6.3 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 8.5%, below the median of its sector (47.2%).
Companies similar to NAQI
Companies in the same business, of comparable size and area, outside its group.
- -Heel Belgium Manufacture of pharmaceutical preparations Ghent · balance sheet €3.17m
- Belgica Manufacture of pharmaceutical preparations Ghent · balance sheet 567,720 €
- Thameus Manufacture of pharmaceutical preparations Liège · balance sheet 502,659 €
- Prieka Manufacture of pharmaceutical preparations Etterbeek · balance sheet 440,325 €
- Phenix Property Manufacture of pharmaceutical preparations Hoogstraten · balance sheet €1.13m
- Laboratorium Cosdam - Laboratoire Cosdam Manufacture of other food products n.e.c. Wijnegem · balance sheet €1.95m
- 272BIO Manufacture of pharmaceutical preparations Ghent · balance sheet 709,601 €
- Unda Manufacture of pharmaceutical preparations Aywaille · balance sheet 517,605 €
Frequently asked questions about NAQI
What is the revenue of NAQI?
NAQI files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of NAQI?
In Belgium, the VAT number is the company number prefixed with BE: BE0428898564 for NAQI, if the company is VAT-registered. Its company number (CBE) is 0428.898.564.
Where is the registered office of NAQI?
According to the CBE register, the registered office of NAQI is in 3545 Halen.
What is the equity of NAQI?
At the close of the 2025 financial year, the equity of NAQI amounts to 106,161 €, a solvency of 8.5% of total assets.
How many people work at NAQI?
6.3 full-time equivalents on average according to the 2025 social balance sheet.
Who manages NAQI?
The register lists 3 active mandates at NAQI. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of NAQI
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →